RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Shanghai’s I-Mab Biopharma signed a memorandum of understanding with Bio-Cancer Treatment International of Hong Kong to collaborate on developing BCT’s arginine depletion therapy in autoimmune diseases and cancers. As part of the work, the two companies will develop biomarkers for arginine and other immunologic targets in the tumor microenvironment for cancer immunotherapy. I-Mab will establish a translational medicine lab in Hong Kong to advance the project.
Source: China Biotoday
